Cargando…

Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study

PURPOSE: Treatments for patients with metastatic castration-resistant prostate cancer (mCRPC) have expanded rapidly. They include the chemotherapies docetaxel and cabazitaxel, hormonal drugs abiraterone and enzalutamide, and best supportive care (BSC). Cabazitaxel has proven to be the last life-prol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kreis, Kristine, Horenkamp-Sonntag, Dirk, Schneider, Udo, Zeidler, Jan, Glaeske, Gerd, Weissbach, Lothar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160066/ https://www.ncbi.nlm.nih.gov/pubmed/32474839 http://dx.doi.org/10.1007/s41669-020-00219-6

Ejemplares similares

Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims
por: Freedland, Stephen J., et al.
Publicado: (2023)

Prevalence and Medications of Atopic Dermatitis in Germany: Claims Data Analysis
por: Hagenström, Kristina, et al.
Publicado: (2021)

Epidemiology and cost of seasonal influenza in Germany - a claims data analysis
por: Scholz, Stefan, et al.
Publicado: (2019)

Follow-up of 3 Million Persons Undergoing Colonoscopy in Germany: Utilization of Repeat Colonoscopies and Polypectomies Within 10 Years
por: Schwarz, Sarina, et al.
Publicado: (2020)

Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
por: Rana, Dikshyanta, et al.
Publicado: (2021)

Healthcare costs and resource utilization of asthma in Germany: a claims data analysis
por: Jacob, Christian, et al.
Publicado: (2015)

Patterns of ambulatory medical care utilization in elderly patients with special reference to chronic diseases and multimorbidity - Results from a claims data based observational study in Germany
por: van den Bussche, Hendrik, et al.
Publicado: (2011)

Which chronic diseases and disease combinations are specific to multimorbidity in the elderly? Results of a claims data based cross-sectional study in Germany
por: van den Bussche, Hendrik, et al.
Publicado: (2011)

Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis
por: Schultz, Neil M., et al.
Publicado: (2018)

Specialist involvement and referral patterns in ambulatory medical care for patients with dementia in Germany: results of a claims data based case-control study
por: van den Bussche, Hendrik, et al.
Publicado: (2011)

Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis
por: Kocaata, Zeki, et al.
Publicado: (2022)

Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
por: Dragomir, Alice, et al.
Publicado: (2014)

Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer
por: Pollard, Matthew E., et al.
Publicado: (2017)

The cost impact of disease progression to metastatic castration-sensitive prostate cancer
por: Trinh, Quoc-Dien, et al.
Publicado: (2022)

Use of guideline-recommended drug therapy in patients undergoing percutaneous coronary intervention for stable coronary heart disease in Germany: a multilevel analysis of nationwide routine data
por: Frank-Tewaag, Julia, et al.
Publicado: (2020)

Claims Data Analysis on the Dispensing of Tricyclic Antidepressants Among Patients With Dementia in Germany
por: Hessmann, Philipp, et al.
Publicado: (2019)

One-year follow-up healthcare costs of patients diagnosed with skin cancer in Germany: a claims data analysis
por: Speckemeier, Christian, et al.
Publicado: (2022)

Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer
por: Su, Dan, et al.
Publicado: (2021)

Realities in cost-effectiveness analyses: a study of castration-resistant prostate cancer patients using a medical claims database
por: Kunisawa, Susumu, et al.
Publicado: (2015)

Time-Dependent Impact of Diabetes on Mortality in Patients With Stroke: Survival up to 5 years in a health insurance population cohort in Germany
por: Icks, Andrea, et al.
Publicado: (2012)

Estimates of Toxoplasmosis Incidence Based on Healthcare Claims Data, Germany, 2011–2016
por: Krings, Amrei, et al.
Publicado: (2021)

Comorbidities and costs in HIV patients: A retrospective claims database analysis in Germany
por: Christensen, Stefan, et al.
Publicado: (2019)

Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union
por: Clark, Marci J, et al.
Publicado: (2014)

Regional variation in coronary angiography rates: the association with supply factors and the role of indication: a spatial analysis
por: Frank-Tewaag, Julia, et al.
Publicado: (2022)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Medication Adherence and Healthcare Costs in Chronically Ill Patients Using German Claims Data
por: Wendl, Johannes, et al.
Publicado: (2023)

Impact of regional socioeconomic variation on coordination and cost of ambulatory care: investigation of claims data from Bavaria, Germany
por: Mehring, Michael, et al.
Publicado: (2017)

Health care utilizations and costs of Campylobacter enteritis in Germany: A claims data analysis
por: Schorling, Elisabeth, et al.
Publicado: (2023)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

“We talk it over” - mixed-method study of interdisciplinary collaborations in private practice among urologists and oncologists in Germany
por: Beermann, Sandra, et al.
Publicado: (2014)

Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis
por: Zhong, Lixian, et al.
Publicado: (2013)

Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study
por: Restelli, Umberto, et al.
Publicado: (2017)

Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan
por: Okumura, Hiroyuki, et al.
Publicado: (2021)

Perception of castration value over cost in the metastatic prostate cancer scenario: a contemporary pharmacoeconomic perspective
por: Col, Luciana Saboya Brito Dal, et al.
Publicado: (2021)

Healthcare Resource Utilization and Cost Burden of BCG-Treated Non-Muscle Invasive Bladder Cancer Patients in Germany: A Retrospective Claims Analysis
por: Quignot, Nadia, et al.
Publicado: (2023)

Second-line Hormonal Therapy for the Management of Metastatic Castration-resistant Prostate Cancer: a Real-World Data Study Using a Claims Database
por: Liu, Jui-Ming, et al.
Publicado: (2020)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_60dkdrq10mr2casdqrmia6ud7c